A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia

Back to Search
Print
Bookmark Trial

NCT00424372

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Nagoya, Aichi, , Japan
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Postherpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients who completed the 13-week treatment of postherpetic neuralgia in Study A0081120.

- Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients who experienced serious adverse events in the preceding study (A0081120) that
were determined by the investigator or the study sponsor to be causally related to the
study medication.


- Patients exhibiting treatment non-compliance in the preceding study (A0081120)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Postherpetic NeuralgiaRN624 For Pain Of Post-Herpetic Neuralgia
NCT00568321
  1. Anniston, Alabama
  2. Litchfield Park, Arizona
  3. Phoenix, Arizona
  4. Atlantis, Florida
  5. Clearwater, Florida
  6. Largo, Florida
  7. Miami, Florida
  8. Palm Beach Gardens, Florida
  9. Sunrise, Florida
  10. Tampa, Florida
  11. Topeka, Kansas
  12. Towson, Maryland
  13. N. Dartmouth, Massachusetts
  14. Ann Arbor, Michigan
  15. Edina, Minnesota
  16. St Louis, Missouri
  17. Asheville, North Carolina
  18. Cleveland, Ohio
  19. Dayton, Ohio
  20. Kettering, Ohio
  21. Altoona, Pennsylvania
  22. Duncansville, Pennsylvania
  23. Bryan, Texas
  24. Dallas, Texas
  25. Houston, Texas
  26. San Antonio, Texas
  27. Richmond, Virginia
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postherpetic NeuralgiaPH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia
NCT00614705
  1. Vina del Mar, V Region
  2. Moscow,
  3. St. Petersburg,
  4. St. Petersburg,
  5. Yaroslavl,
  6. Cadiz,
  7. Madrid,
  8. Ourense,
  9. Sevilla,
  10. Valencia,
  11. Linkoping,
  12. Stockholm,
  13. Stockholm,
  14. Dnipropetrovsk,
  15. Donetsk,
  16. Kharkiv,
  17. Kharkiv,
  18. Kharkiv,
  19. Kyiv,
  20. Odessa,
  21. Simferopol,
  22. Bexhill on Sea, East Sussex
  23. Blackpool, Lancashire
  24. Weybridge, Surrey
  25. Solihull,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postherpetic NeuralgiaA 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
NCT00394901
  1. Nagoya, Aichi
  2. Ichikawa, Chiba
  3. Urayasu, Chiba
  4. Kasuga, Fukuoka
  5. Kasuya-gun, Fukuoka
  6. Maebaru, Fukuoka
  7. Maebashi, Gunma
  8. Takasaki, Gunma
  9. Asahikawa, Hokkaido
  10. Sapporo, Hokkaido
  11. Akashi, Hyogo
  12. Amagasaki, Hyogo
  13. Himeji, Hyogo
  14. Kobe, Hyogo
  15. Nishinomiya, Hyogo
  16. Tsuchiura, Ibaraki
  17. Sagamihara, Kanagawa
  18. Yokohama, Kanagawa
  19. Sendai, Miyagi
  20. Beppu, Ohita
  21. Kishiwada, Osaka
  22. Takatsuki, Osaka
  23. Kawaguchi, Saitama
  24. Kitamoto, Saitama
  25. Tokorozawa, Saitama
  26. Adachi-ku, Tokyo
  27. Arakawa-ku, Tokyo
  28. Bunkyo-ku, Tokyo
  29. Edogawa-ku, Tokyo
  30. Mitaka, Tokyo
  31. Nakano-ku, Tokyo
  32. Shinagawa-ku, Tokyo
  33. Shinjuku-ku, Tokyo
  34. Suginami-ku, Tokyo
  35. Toshima-ku, Tokyo
  36. Fukuoka,
  37. Fukushima,
  38. Osaka,
  39. Saitama,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Postherpetic NeuralgiaPilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
NCT01603394
  1. Leesburg, Florida
  2. Lexington, Kentucky
  3. Raleigh, North Carolina
  4. Jekintown, Pennsylvania
  5. Senftenberg, A-3541
  6. Wien,
  7. Schwerin,
  8. Pretoria, Gauteng
  9. Paarl, Western Cape
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin For Postherpetic Neuralgia
Official Title  ICMJE A Long-Term Study To Evaluate Safety And Efficacy Of Pregabalin In The Treatment Of Postherpetic Neuralgia
Brief Summary To evaluate the safety of the long-term use of pregabalin.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Neuralgia, Postherpetic
Intervention  ICMJE Drug: pregabalin
Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
Study Arms  ICMJE Experimental: pregabalin
Intervention: Drug: pregabalin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: September 24, 2008)		126
Original Enrollment  ICMJE
 (submitted: January 18, 2007)		150
Actual Study Completion Date  ICMJE August 2008
Actual Primary Completion Date August 2008   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients who completed the 13-week treatment of postherpetic neuralgia in Study A0081120.
  • Patients must be able to understand and cooperate with study procedures and have signed a written informed consent prior to entering the study.

Exclusion Criteria:

  • Patients who experienced serious adverse events in the preceding study (A0081120) that were determined by the investigator or the study sponsor to be causally related to the study medication.
  • Patients exhibiting treatment non-compliance in the preceding study (A0081120)
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00424372
Other Study ID Numbers  ICMJE A0081121
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Director, Clinical Trials Disclosure Group, Pfizer, Inc.
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP